TP
MRNA icon

Theleme Partners’s Moderna MRNA Stock Holding History

Theleme Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,972
Closed -$53.3M – 13
2024
Q3 		$53.3M Buy
7,972
+1,768
+28% +$162K 3.05% 9
2024
Q2 		$73.7M Sell
6,204
-1,433,796
-100% -$181M 3.54% 8
2024
Q1 		$153M Sell
1,440,000
-574,000
-29% -$57.9M 7.78% 4
2023
Q4 		$200M Buy
+2,014,000
New +$169M 9.55% 4
2023
Q1 		– Sell
-282,000
Closed -$50.7M – 12
2022
Q4 		$50.7M Buy
+282,000
New +$46.1M 1.91% 10

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners's MRNA Position: Q1 2026 in Review

Theleme Partners reduced its Moderna (MRNA) stake by 0.42% in Q1 2026, selling an estimated $1.57M and leaving 8,048,245 shares worth $409M. The position accounts for 27.24% of the portfolio, ranked #1.

Theleme Partners first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.52B in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Theleme Partners held 8,048,245 shares of Moderna worth $409M as of Q1 2026.
  • Theleme Partners sold 33,565 Moderna shares in Q1 2026, an estimated $1.57M.
  • Moderna made up 27.24% of Theleme Partners's portfolio in Q1 2026, its #1 holding.
  • Theleme Partners first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
  • Theleme Partners's Moderna position peaked at $1.52B in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Theleme Partners's 13F filing for Q1 2026, filed 15 May 2026.